1-20 of 36
Judy E. Garber
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 2262: A case-control analysis of germline pathogenic variants among patients with sarcoma

Adela Rodriguez Hernandez, Miki Horiguchi, Carolyn Horton, Linda M Polfus, Brittany L. Bychkovsky, Colin Young, Suzanne George George, Priscilla Merriam, Judy E Garber, Huma Q Rana
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 2262.
https://doi.org/10.1158/1538-7445.AM2025-2262
Published: 21 April 2025
View articletitled, Abstract 2262: A case-control analysis of germline pathogenic variants among patients with sarcoma
Journal Articles

Abstract 259: Germline p53 R181 mutants and DNA binding cooperativity in tumorigenesis

Renyta Moses, Alexandra Indeglia, Alison S. Levine, Ryan Hausler, Gregory Kelly, Sven A. Miller, Melissa Heller, Anh N. Le, Wendy Kohlmann, Anne Naumer, Jennie Vagher, Sophie H. Cahill, Luke D. Maese, John Karanicolas, Judy E. Garber, Maureen E. Murphy, Kara N. Maxwell
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 259.
https://doi.org/10.1158/1538-7445.AM2025-259
Published: 21 April 2025
View articletitled, Abstract 259: Germline p53 R181 mutants and DNA binding cooperativity in tumorigenesis
Journal Articles

Abstract 7403: Colorectal neoplasia rates in Li Fraumeni syndrome

Sophia R. Spiegel, Caitlin Orr, Mikia J. Croom, Nicolas U. Edgar, Sophie R. Cahill, Anh N. Le, Madeline Good, Jo Anson, Soren Feola, Casey Mehrhoff, Anne Naumer, Jennie Vagher, Luke D. Maese, Judy E. Garber, Asaf Maoz, Bryson W. Katona, Suzanne P. MacFarland, Kara N. Maxwell
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 7403.
https://doi.org/10.1158/1538-7445.AM2025-7403
Published: 21 April 2025
View articletitled, Abstract 7403: Colorectal neoplasia rates in Li Fraumeni syndrome
Journal Articles

Abstract P5-12-03: Intratumor heterogeneity and intrinsic immune activation are associated with response to chemotherapy in BRCA-related breast cancers

Felipe Batalini, Doga C. Gulhan, Xanthi Lida Katopodi, Nikolas Kalavros, Antuan Tran, Dimitra Karagkouni, Emily Stern-Gatof, Stuart Schnitt, Judy E. Garber, Gerburg M. Wulf, Peter J. Park, Ioannis Vlachos, Nadine Tung
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P5-12-03.
https://doi.org/10.1158/1538-7445.SABCS22-P5-12-03
Published: 01 March 2023
View articletitled, Abstract P5-12-03: Intratumor heterogeneity and intrinsic immune activation are associated with response to chemotherapy in BRCA-related breast cancers
Journal Articles

Abstract A029: A randomized study of two Strategies of remote Genetic Education, Risk Assessment, and Testing (GENERATE) for family members of patients with pancreatic cancer

Nicolette J. Rodriguez, C. Sloane Furniss, Matthew B. Yurgelun, Chinedu Ukaegbu, Pamela E. Constantinou, Ileana Fortes, Alyson Caruso, Alison N. Schwartz, Jill E. Stopfer, Meghan Underhill-Blazey, Barbara Kenner, Scott H. Nelson, Sydney Okumura, Alicia Y. Zhou, Tara B. Coffin, Hajime Uno, Miki Horiguchi, Allyson J. Ocean, Florencia McAllister, Andrew M. Lowy, Scott M. Lippman, Alison P. Klein, Lisa Madlensky, Gloria M. Petersen, Judy E. Garber, Michael G. Goggins, Anirban Maitra, Sapna Syngal
Journal: Cancer Research
Cancer Res (2022) 82 (22_Supplement): A029.
https://doi.org/10.1158/1538-7445.PANCA22-A029
Published: 15 November 2022
View articletitled, Abstract A029: A randomized study of two Strategies of remote Genetic Education, Risk Assessment, and Testing (GENERATE) for family members of patients with pancreatic cancer
Journal Articles

Abstract P2-09-03: Pathogenic variants among female breast cancer patients with a subsequent cancer demonstrate preventable cancer burden

Brittany L. Bychkovsky, Min-Tzu Lo, Amal Yussuf, Carrie Horton, Parichehr Hemyari, Holly LaDuca, Judy E. Garber, Huma Q. Rana
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-09-03.
https://doi.org/10.1158/1538-7445.SABCS21-P2-09-03
Published: 15 February 2022
View articletitled, Abstract P2-09-03: Pathogenic variants among female breast cancer patients with a subsequent cancer demonstrate preventable cancer burden
Journal Articles

Abstract P3-08-01: Clonal hematopoiesis of indeterminate potential (CHIP) in metastatic triple negative breast cancer

Katheryn Santos, Qingchun Jin, Peter G. Miller, Ashka Patel, Gregory J. Kirkner, Janet L. Files, Melissa E. Hughes, Samantha M. Stokes, Nabihah Tayob, Daniel G. Stover, Christopher J. Gibson, Eric P. Winer, Nancy U. Lin, Judy E. Garber, Heather A. Parsons
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P3-08-01.
https://doi.org/10.1158/1538-7445.SABCS21-P3-08-01
Published: 15 February 2022
View articletitled, Abstract P3-08-01: Clonal hematopoiesis of indeterminate potential (CHIP) in metastatic triple negative breast cancer
Journal Articles

Abstract GS4-09: Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer

Patricia A Ganz, Hanna Bandos, Tanja Spanic, Sue Friedman, Volkmar Müller, Sherko Kümmel, Suzette Delaloge, Etienne Brain, Masakazu Toi, Hideko Yamauchi, Eduardo-Martínez de Dueñas, Anne Armstrong, Seock-Ah Im, Chuangui Song, Hong Zheng, Tomasz Sarosiek, Priyanka Sharma, Giovanna Rossi, Priya Rastogi, Anitra Fielding, Richard D Gelber, Christine Campbell, Judy E Garber, Charles E Geyer, Jr, Andrew NJ Tutt, On behalf of the OlympiA Trial Steering Committeeand Investigators
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): GS4-09.
https://doi.org/10.1158/1538-7445.SABCS21-GS4-09
Published: 15 February 2022
View articletitled, Abstract GS4-09: Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer
Journal Articles

Abstract PO-013: Comparison of novel healthcare delivery models on the uptake of genetic education and testing in families with a history of pancreatic cancer: The GENetic Education, Risk Assessment and TEsting (GENERATE) study

Nicolette J. Rodriguez, Constance S. Furniss, Matthew B. Yurgelun, Chinedu Ukaegbu, Pamela E. Constantinou, Alison N. Schwartz, Jill Stopfer, Meghan Underhill-Blazey, Barbara Kenner, Scott Nelson, Sydney Okumura, Sherman Law, Alicia Y. Zhou, Tara B. Coffin, Hajime Uno, Allyson Ocean, Florencia McAllister, Andrew M. Lowy, Scott M. Lippman, Alison P. Klein, Lisa Madlensky, Gloria M. Petersen, Judy E. Garber, Michael G. Goggins, Anirban Maitra, Sapna Syngal
Journal: Cancer Research
Cancer Res (2021) 81 (22_Supplement): PO-013.
https://doi.org/10.1158/1538-7445.PANCA21-PO-013
Published: 15 November 2021
View articletitled, Abstract PO-013: Comparison of novel healthcare delivery models on the uptake of genetic education and testing in families with a history of pancreatic cancer: The GENetic Education, Risk Assessment and TEsting (GENERATE) study
Journal Articles

Abstract OT-20-01: Genetic testing for all breast cancer patients (get facts)

Anna Weiss, Danielle Braun, Jill Stopfer, Daniel Desantis, Meaghan Dwan, Dillon Davis, Anjali Jha, Laura Dominici, Shoshana Rosenberg, Tari A. King, Elizabeth A Mittendorf, Mehra Golshan, Huma Q Rana, Judy E Garber
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): OT-20-01.
https://doi.org/10.1158/1538-7445.SABCS20-OT-20-01
Published: 15 February 2021
View articletitled, Abstract OT-20-01: Genetic testing for all breast cancer patients (get facts)
Journal Articles

A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers

Jacquelyn Powers, Emilia M. Pinto, Thibaut Barnoud, Jessica C. Leung, Tetyana Martynyuk, Andrew V. Kossenkov, Aaron H. Philips, Heena Desai, Ryan Hausler, Gregory Kelly, Anh N. Le, Marilyn M. Li, Suzanne P. MacFarland, Louise C. Pyle, Kristin Zelley, Katherine L. Nathanson, Susan M. Domchek, Thomas P. Slavin, Jeffrey N. Weitzel, Jill E. Stopfer, Judy E. Garber, Vijai Joseph, Kenneth Offit, Jill S. Dolinsky, Stephanie Gutierrez, Kelly McGoldrick, Fergus J. Couch, Brooke Levin, Morris C. Edelman, Carolyn Fein Levy, Sheri L. Spunt, Richard W. Kriwacki, Gerard P. Zambetti, Raul C. Ribeiro, Maureen E. Murphy, Kara N. Maxwell
Journal: Cancer Research
Cancer Res (2020) 80 (17): 3732–3744.
https://doi.org/10.1158/0008-5472.CAN-20-1390
Published: 02 September 2020
View articletitled, A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers
Open the PDF for A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers in another window
Includes: Supplementary data
Journal Articles

Abstract 1120: Randomized clinical trial of a flaxseed lignan in pre-menopausal women at high risk for development of breast cancer

Carol J. Fabian, Seema A. Khan, Judy E. Garber, William C. Dooley, Lisa D. Yee, Carola M. Zalles, Trina Metheny, Teresa A. Phillips, Jinxiang Hu, Brian K. Petroff, Stephen D. Hursting, Bruce F. Kimler
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1120.
https://doi.org/10.1158/1538-7445.AM2020-1120
Published: 15 August 2020
View articletitled, Abstract 1120: Randomized clinical trial of a flaxseed lignan in pre-menopausal women at high risk for development of breast cancer
Journal Articles

Abstract GS6-03: Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers (BRCA carriers) with HER2-negative breast cancer: Results from the INFORM trial (TBCRC 031)

Nadine Tung, Banu Arun, Erin Hofstatter, Michele R. Hacker, Deborah L. Toppmeyer, Steven J. Isakoff, Virginia Borges, Robert D. Legare, Claudine Isaacs, Antonio C. Wolff, Paul K. Marcom, Erica L. Mayer, Paulina B. Lange, Andrew J. Goss, Ian E. Krop, Eric P. Winer, Stuart J. Schnitt, Judy E. Garber
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): GS6-03.
https://doi.org/10.1158/1538-7445.SABCS19-GS6-03
Published: 15 February 2020
View articletitled, Abstract GS6-03: Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers (BRCA carriers) with HER2-negative breast cancer: Results from the INFORM trial (TBCRC 031)
Journal Articles

Abstract P5-04-01: PARP inhibition modulates the infiltration, phenotype and function of tumor-associated macrophages (TAMs) in BRCA-associated breast cancer and can be augmented by harnessing the anti-tumor potential of TAMs

Jennifer L Guerriero, Anita K Mehta, Emily M Cheney, Jessica A. Castrillon, Jia-Ren Lin, Mateus de Oliveira Taveira, Olmo Sonzogni, Constantia Pantelidou, Christina A Hartl, William M Oldham, Nathan T Johnson, Sarah A Boswell, Marian Kalocsay, Matthew J Berberich, Sholin Mei, Dan Wang, Shawn Johnson, Brett Gross, Deborah A Dillon, Mikel Lipschitz, Evisa Gjini, Scott Rodig, Sandro Santagata, Judy E Garber, Nadine Tung, Peter Sorger, Geoffrey I Shapiro, Gerburg M Wulf, Elizabeth A Mittendorf
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P5-04-01.
https://doi.org/10.1158/1538-7445.SABCS19-P5-04-01
Published: 15 February 2020
View articletitled, Abstract P5-04-01: PARP inhibition modulates the infiltration, phenotype and function of tumor-associated macrophages (TAMs) in BRCA-associated breast cancer and can be augmented by harnessing the anti-tumor potential of TAMs
Journal Articles

Abstract 2406: A general probabilistic algorithm to predict de novo mutations in familial diseases as demonstrated in Li-Fraumeni Syndrome

Xuedong Pan, Fan Gao, Elissa B. Dodd, Jasmina Bojadzieva, Phuong L. Mai, Valen E. Johnson, Kristin Zelley, Kim E. Nichols, Judy E. Garber, Sharon A. Savage, Louise C. Strong, Wenyi Wang
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 2406.
https://doi.org/10.1158/1538-7445.AM2019-2406
Published: 01 July 2019
View articletitled, Abstract 2406: A general probabilistic algorithm to predict de novo mutations in familial diseases as demonstrated in Li-Fraumeni Syndrome
Journal Articles

Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma

Xiaomu Wei, M. Nieves Calvo-Vidal, Siwei Chen, Gang Wu, Maria V. Revuelta, Jian Sun, Jinghui Zhang, Michael F. Walsh, Kim E. Nichols, Vijai Joseph, Carrie Snyder, Celine M. Vachon, James D. McKay, Shu-Ping Wang, David S. Jayabalan, Lauren M. Jacobs, Dina Becirovic, Rosalie G. Waller, Mykyta Artomov, Agnes Viale, Jayeshkumar Patel, Jude Phillip, Selina Chen-Kiang, Karen Curtin, Mohamed Salama, Djordje Atanackovic, Ruben Niesvizky, Ola Landgren, Susan L. Slager, Lucy A. Godley, Jane Churpek, Judy E. Garber, Kenneth C. Anderson, Mark J. Daly, Robert G. Roeder, Charles Dumontet, Henry T. Lynch, Charles G. Mullighan, Nicola J. Camp, Kenneth Offit, Robert J. Klein, Haiyuan Yu, Leandro Cerchietti, Steven M. Lipkin
Journal: Cancer Research
Cancer Res (2018) 78 (10): 2747–2759.
https://doi.org/10.1158/0008-5472.CAN-17-1900
Published: 14 May 2018
View articletitled, Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma
Open the PDF for Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

Abstract 4265: Risks of familial breast cancer associated with known and proposed breast cancer susceptibility genes

Kara N. Maxwell, Thomas Paul Slavin, Jenna M. Lilyquist, Joseph Vijai, Susan L. Neuhausen, Steven N. Hart, Vignesh Ravichandran, Tinu Thomas, Ann Maria, Kasmintan A. Schrader, Raymond Moore, Chunling Hu, Brad Wubbenhorst, Brandon M. Wenz, Kurt D'Andrea, Susan M. Domchek, Mark E. Robson, Paulo Peterlongo, Paolo Radice, James M. Ford, Judy E. Garber, Csilla Szabo, Kenneth Offit, Katherine L. Nathanson, Fergus J. Couch, Jeffrey N. Weitzel
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 4265.
https://doi.org/10.1158/1538-7445.AM2017-4265
Published: 01 July 2017
View articletitled, Abstract 4265: Risks of familial breast cancer associated with known and proposed breast cancer susceptibility genes
Journal Articles

Abstract 3376: Reprogramming the estrogen signaling network is a potential mechanism for human breast tumorigenesis

David Chi, Hari Singhal, Lewyn Li, Henry W. Long, Judy E. Garber, Myles A. Brown
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 3376.
https://doi.org/10.1158/1538-7445.AM2017-3376
Published: 01 July 2017
View articletitled, Abstract 3376: Reprogramming the estrogen signaling network is a potential mechanism for human breast tumorigenesis
Journal Articles

Precancer Atlas to Drive Precision Prevention Trials

Avrum Spira, Matthew B. Yurgelun, Ludmil Alexandrov, Anjana Rao, Rafael Bejar, Kornelia Polyak, Marios Giannakis, Ali Shilatifard, Olivera J. Finn, Madhav Dhodapkar, Neil E. Kay, Esteban Braggio, Eduardo Vilar, Sarah A. Mazzilli, Timothy R. Rebbeck, Judy E. Garber, Victor E. Velculescu, Mary L. Disis, Douglas C. Wallace, Scott M. Lippman
Journal: Cancer Research
Cancer Res (2017) 77 (7): 1510–1541.
https://doi.org/10.1158/0008-5472.CAN-16-2346
Published: 02 April 2017
View articletitled, Precancer Atlas to Drive Precision Prevention Trials
Open the PDF for Precancer Atlas to Drive Precision Prevention Trials in another window
Journal Articles

Abstract P3-06-11: Homologous recombination deficiency (HRD) assay predicts response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer

Andrea L Richardson, Daniel P Silver, Zoltan Szallasi, Nicolai J Birkbak, Zhigang C Wang, J Dirk Iglehart, Erica L Mayer, Eric P Winer, Nadine M Tung, Paula D Ryan, Steven J Isakoff, William T Barry, April Greene-Collozi, Alexander Gutin, Julia Reid, Chris Neff, Joshua Jones, Kirsten Timms, Anne-Renee Hartman, Judy E Garber
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P3-06-11.
https://doi.org/10.1158/1538-7445.SABCS14-P3-06-11
Published: 01 May 2015
View articletitled, Abstract P3-06-11: Homologous recombination deficiency (HRD) assay predicts response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer